Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.22 USD
Change Today +0.19 / 6.27%
Volume 75.4K
ROSG On Other Exchanges
Symbol
Exchange
Berlin
As of 2:25 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Open
$3.03
Previous Close
$3.03
Day High
$3.25
Day Low
$2.95
52 Week High
02/17/15 - $5.55
52 Week Low
12/9/14 - $2.07
Market Cap
46.7M
Average Volume 10 Days
98.3K
EPS TTM
--
Shares Outstanding
14.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. It is also developing a test for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood or urine based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection; blood-based microRNA biomarkers to develop a diagnostic test for early diagnosis of heart failure and refined risk stratification of patients following myocardial infarction; tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer; tissue-based microRNA biomarkers to develop a test for the pre-surgical risk stratification of patients with endometrial cancer; and microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.

52 Employees
Last Reported Date: 03/16/15
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $800.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $141.0K
Chief Medical Officer
Total Annual Compensation: $313.0K
Chief Legal Officer and Secretary
Total Annual Compensation: $273.0K
Chief Scientific Officer
Total Annual Compensation: $163.0K
Compensation as of Fiscal Year 2014.

rosetta genomics ltd (ROSG) Key Developments

Rosetta Genomics, Ltd. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM

Rosetta Genomics, Ltd. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 02:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Kenneth A. Berlin, Chief Executive Officer and President.

Rosetta Genomics Ltd. Announces Agreement with MultiPlan, Inc. for its PersonalizeDx Suite of Testing Services

Rosetta Genomics Ltd. announced that PersonalizeDx has executed a network participation agreement with MultiPlan Inc. for the entire suite of PersonalizeDx testing and services effective July 1, 2015. More than 900,000 healthcare providers participate in MultiPlan's networks, and the company reprices 40 million claims each year. It is estimated that 68 million Americans have access to MultiPlan's networks. In addition to offering regional PPO networks in Wisconsin and the southwest, Multi-Plan offers the leading independent national primary PPO and one of the large complementary networks in the United States. As a result of this agreement, PersonalizeDx is one of those participating healthcare providers. A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third party administrator to provide health care at reduced rates to the insurer's or administrator's clients.

Rosetta Genomics Ltd. Launches OncoGxOne

Rosetta Genomics Ltd. announced the commercial launch of OncoGxOne, Admera Health's next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. OncoGxOne was recently approved as a Laboratory Developed Test and is the fifth new product introduced by Rosetta Genomics in 2015. OncoGxOne interrogates all types of genomic aberrations in 64 genes, specifically 56 related to cancer targeted therapy and 8 related to chemotherapy. This test covers all exons and 5 and 3 UTRs for each gene, as well as all introns that harbor potential gene translocation breakpoints. OncoGxOne is performed on a modest-sized pathology sample in the standard format of FFPE tissue, the same as Rosetta's other clinical microRNA-based diagnostics. OncoGxOne will compete with currently available genomic profiling offerings through next-generation sequencing platforms that can identify potentially actionable cancer-driving mutations, which can be targeted by specific therapies. OncoGxOne joins Rosetta's expanding product portfolio of molecular diagnostics products and complements suite of tests including the Rosetta Cancer Origin Test for physicians managing patients with either cancers of unknown or uncertain origin or those not responding to current treatments due to the uncertainty of diagnosis. Combining comprehensive genomic profiling and microRNA profiling offers a unique solution to help clinicians optimize effective therapeutic decision-making.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.22 USD +0.19

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $30.00 USD -0.47
Genomic Health Inc $26.68 USD +0.60
NeoGenomics Inc $6.02 USD -0.05
Response Genetics Inc $0.15 USD +0.003
Veracyte Inc $11.64 USD -0.32
View Industry Companies
 

Industry Analysis

ROSG

Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.3x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit www.rosettagenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.